ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Free Report) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $8.50.

Several research analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a research note on Wednesday, December 18th. Finally, Jefferies Financial Group cut ALX Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the company from $12.00 to $2.00 in a research report on Thursday, December 19th.

Get Our Latest Research Report on ALXO

Insider Activity at ALX Oncology

In related news, Director Rekha Hemrajani acquired 30,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average cost of $1.55 per share, with a total value of $46,500.00. Following the purchase, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. The trade was a 1,000.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders sold 14,443 shares of company stock valued at $23,309. Insiders own 33.40% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its stake in shares of ALX Oncology by 31.6% in the second quarter. Bank of New York Mellon Corp now owns 104,966 shares of the company’s stock worth $633,000 after buying an additional 25,199 shares during the last quarter. Rhumbline Advisers lifted its position in ALX Oncology by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after acquiring an additional 5,360 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in ALX Oncology by 87.2% during the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after acquiring an additional 204,100 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology in the second quarter valued at about $63,000. Finally, Inspire Investing LLC increased its stake in shares of ALX Oncology by 77.1% in the second quarter. Inspire Investing LLC now owns 58,707 shares of the company’s stock worth $354,000 after purchasing an additional 25,551 shares during the period. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Price Performance

Shares of ALXO opened at $1.63 on Friday. The business’s 50-day moving average is $1.58 and its 200-day moving average is $2.56. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The company has a market capitalization of $85.97 million, a price-to-earnings ratio of -0.55 and a beta of 0.98. ALX Oncology has a fifty-two week low of $1.19 and a fifty-two week high of $17.83.

ALX Oncology Company Profile

(Get Free Report

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

Featured Articles

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.